- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07667517
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Background and rationale: Finerenone is an oral, highly selective nonsteroidal mineralocorticoid receptor antagonist approved in China for the treatment of chronic kidney disease associated with type 2 diabetes (with albuminuria). In the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone added to a maximum tolerated dose of a renin-angiotensin system inhibitor significantly and durably reduced the urine albumin-to-creatinine ratio (UACR) and lowered the risk of kidney and cardiovascular events, with a manageable hyperkalemia risk. A meaningful reduction in albuminuria is an established early surrogate for slowing CKD progression and reducing cardiovascular risk. This study evaluates whether finerenone can achieve early regression of albuminuria in patients with type 2 diabetes and CKD.
Design: This is a multicenter, randomized, double-blind, placebo-controlled trial conducted at up to 12 sites in China. A planned 148 participants are allocated 1:1 to finerenone or matching placebo using central, block randomization (interactive response technology), stratified by baseline UACR (<300 vs >=300 mg/g). Participants and investigators are blinded; placebo tablets are identical in appearance to finerenone, and intervention-period UACR samples are assayed centrally after study completion to preserve blinding.
Population: Eligible participants are adults with type 2 diabetes and CKD (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who have received a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days and have serum potassium <= 5.0 mmol/L.
Intervention and dose titration: The starting dose is determined by screening eGFR: 10 mg once daily for 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg once daily for eGFR >= 60 mL/min/1.73 m^2. The dose is up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR at scheduled and, if needed, unscheduled safety visits. Treatment continues for 180 days.
Visit schedule: a screening period (Day -30 to -1; V1); a treatment period ; and an off-treatment follow-up at Day 210 +/- 5 (V7). Unscheduled safety visits and early-discontinuation visits are performed as needed.
Endpoints: The primary endpoint is the albuminuria regression rate at 180 days, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline. Secondary endpoints include the change in UACR, the rate of regression to normoalbuminuria, the proportions achieving >=30/40/50% UACR reduction, KDIGO GFR-Albuminuria category improvement, the change in UACR 30 days after discontinuation, the change in eGFR slope, and the change in blood pressure. Safety endpoints include adverse events, serious adverse events, and adverse events of special interest (notably serum potassium changes and hyperkalemia). Exploratory endpoints also included.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Yuejun Liu
- Número de telefone: +8613472844268
- E-mail: yuejunliu7@126.com
Locais de estudo
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University
-
Contato:
- Zhihong Wang
- Número de telefone: +8613883021919
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Provincial Hospital
-
Contato:
- Junping Wen
- Número de telefone: +8613559925729
-
-
Guangdong
-
Foshan, Guangdong, China
- Sanshui Hospital, Zhujiang Hospital, Southern Medical University
-
Contato:
- Zhen Zhang
- Número de telefone: +8615913162742
-
Guangzhou, Guangdong, China
- Nanfang Hospital, Southern Medical University
-
Contato:
- Junyu Xue
- Número de telefone: +8618613166333
-
-
Jiangsu
-
Nantong, Jiangsu, China
- Nantong First People's Hospital
-
Contato:
- Xueqin Wang
- Número de telefone: +8613813609566
-
Suqian, Jiangsu, China
- The First People's Hospital of Suqian
-
Contato:
- Hong Zhu
- Número de telefone: +8618012186759
-
Suzhou, Jiangsu, China
- Suzhou Science and Technology City Hospital
-
Contato:
- Zhimin Ma
- Número de telefone: +8617715187073
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Xi'an Daxing Hospital
-
Contato:
- Ying Xing
- Número de telefone: +8613991955717
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Zhongshan hospital, Fudan university
-
Contato:
- Yuejuan Liu
- Número de telefone: +8613472844268
-
Shanghai, Shanghai Municipality, China
- Shanghai Municipal Hospital of Traditional Chinese Medicine
-
Contato:
- Feng Tao
- Número de telefone: +8613818808324
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contato:
- Peng Yu
- Número de telefone: 18818211531
- E-mail: ypbaggio@163.com
-
Ningbo, Zhejiang, China
- The First Affiliated Hospital of Ningbo University
-
Contato:
- Li Li
- Número de telefone: +8613757426626
-
Wenzhou, Zhejiang, China
- The First Affiliated Hospital of Wenzhou Medical University
-
Contato:
- Hong Zhu
- Número de telefone: +8613758712421
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- 1. Age >= 18 years at the time of signing informed consent, male or female.
- 2. Type 2 diabetes mellitus.
- 3. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) >= 30 mL/min/1.73 m^2, and UACR 30-2000 mg/g (mean of 3 measurements).
- 4. Serum potassium <= 5.0 mmol/L.
- 5. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.
- 6. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.
Exclusion Criteria:
- 1. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.
- 2. HbA1c >= 8.0%.
- 3. On renal replacement therapy.
- 4. Acute kidney injury within 180 days before the screening visit.
- 5. Hepatic impairment (Child-Pugh class C).
- 6. Blood pressure > 160/100 mmHg, or systolic blood pressure < 90 mmHg, at the screening visit.
- 7. Bilateral renal artery stenosis.
- 8. Known hypersensitivity to the study drug (active substance or excipients).
- 9. Treatment with finerenone within 60 days before screening.
- 10. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.
- 11. NYHA class II-IV heart failure.
- 12. Addison's disease.
- 13. Gastrointestinal surgery that may affect drug absorption.
- 14. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy < 12 months).
- 15. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.
- 16. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.
- 17. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).
- 18. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.
- 19. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.
- 20. History of alcohol or drug abuse.
- 21. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.
- 22. Any other condition deemed by the investigator to make the participant unsuitable for the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Finerenone
Finerenone film-coated tablets, orally once daily, on top of standard background therapy.
Starting dose determined by screening eGFR: 10 mg if 30 <= eGFR < 60 mL/min/1.73
m^2, or 20 mg if eGFR >= 60 mL/min/1.73
m^2.
Dose up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR.
Treatment duration 180 days.
|
Oral finerenone 10 mg or 20 mg once daily, with dose titration by serum potassium and eGFR, for 180 days.
|
|
Comparador de Placebo: Placebo
Matching placebo tablets identical in appearance to finerenone, orally once daily, on top of standard background therapy, following the same dosing and titration schedule.
Treatment duration 180 days.
|
Matching placebo tablets, identical in appearance to finerenone, orally once daily, following the same dosing and titration schedule, for 180 days.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Albuminuria regression rate
Prazo: 180 days
|
Proportion of participants achieving albuminuria regression, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline.
|
180 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio
Prazo: Baseline and 180 days
|
Urinary albumin-to-creatinine ratio will be measured in mg/g.
Percent change from baseline will be calculated as: (Day 180 UACR - baseline UACR) / baseline UACR × 100%.
|
Baseline and 180 days
|
|
Percentage of Participants With Normoalbuminuria
Prazo: 180 days
|
Normoalbuminuria is defined as urinary albumin-to-creatinine ratio less than 30 mg/g at Day 180.
|
180 days
|
|
Percentage of Participants by UACR Reduction Response Category at Day 180
Prazo: Baseline to Day 180
|
Percent reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to Day 180 will be calculated for each participant.
Participants will be classified into one of four mutually exclusive UACR reduction response categories: no more than 30% reduction, more than 30% to no more than 40% reduction, more than 40% to no more than 50% reduction, and more than 50% reduction.
Participants with no reduction or an increase in UACR will be included in the no more than 30% reduction category.
The outcome will be reported as the percentage of participants in each response category.
|
Baseline to Day 180
|
|
Percentage of Participants With Improvement in Kidney Disease: Improving Global Outcomes Albuminuria Category at Day 180
Prazo: Baseline to Day 180
|
Improvement in albuminuria category is defined as a change from A3 to A2 or A1, or from A2 to A1, according to Kidney Disease: Improving Global Outcomes urinary albumin-to-creatinine ratio categories.
|
Baseline to Day 180
|
|
Change From Day 180 to Day 210 in Urinary Albumin-to-Creatinine Ratio
Prazo: Day 180 to Day 210
|
Change in urinary albumin-to-creatinine ratio from Day 180 to Day 210 will be assessed in mg/g, corresponding to the 30-day off-treatment follow-up period.
|
Day 180 to Day 210
|
|
Estimated Glomerular Filtration Rate Slope Through Day 180
Prazo: Baseline through Day 180
|
Estimated glomerular filtration rate will be calculated using the CKD-EPI equation.
The eGFR slope through Day 180 will be estimated from serial eGFR measurements and reported in mL/min/1.73
m2 per year.
|
Baseline through Day 180
|
|
Change From Baseline in Systolic Blood Pressure at Day 180
Prazo: Baseline to Day 180
|
Change in systolic blood pressure from baseline to Day 180 will be assessed in mmHg.
|
Baseline to Day 180
|
|
Change From Baseline in Diastolic Blood Pressure at Day 180
Prazo: Baseline to Day 180
|
Change in diastolic blood pressure from baseline to Day 180 will be assessed in mmHg.
|
Baseline to Day 180
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With Adverse Events
Prazo: From first dose through Day 210
|
The outcome will be reported as the percentage of participants experiencing at least one adverse event from first dose through the end of the 30-day off-treatment follow-up period.
|
From first dose through Day 210
|
|
Percentage of Participants With Serious Adverse Events
Prazo: From first dose through Day 210
|
The outcome will be reported as the percentage of participants experiencing at least one serious adverse event from first dose through the end of the 30-day off-treatment follow-up period.
|
From first dose through Day 210
|
|
Adverse events of special interest (AESI)
Prazo: Up to 210 days
|
Including change in serum potassium and incidence of hyperkalemia, incidence of eGFR decline >30% at Day 30, reversibility of eGFR after discontinuation, acute kidney injury, urogenital infection, severe hypoglycemia, symptomatic hypotension, and ketoacidosis
|
Up to 210 days
|
|
Change in Composite MRI-PDFF-derived Peri-organ Visceral Fat Fraction
Prazo: Baseline and 180 days
|
Abdominal magnetic resonance imaging proton density fat fraction will be used to quantify visceral fat fraction (%) in prespecified perirenal, peripancreatic, and perihepatic regions of interest.
A composite peri-organ visceral fat fraction will be calculated for each participant as the arithmetic mean of the region-specific MRI-PDFF values from the perirenal, peripancreatic, and perihepatic regions.
The outcome will be reported as the percentage-point change in the composite peri-organ visceral fat fraction from baseline to Day 180.
|
Baseline and 180 days
|
|
Change in Urine Metabolomic Composite Score
Prazo: Baseline to Day 180
|
Urine metabolomic features will be measured using a prespecified metabolomics platform.
Normalized metabolite feature intensities will be standardized, and a urine metabolomic composite score will be calculated according to the statistical analysis plan.
The outcome will be reported as change in composite score from baseline to Day 180.
|
Baseline to Day 180
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
- Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
- Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.
- Coresh J, Grams ME, Chen TK. Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care. Am J Kidney Dis. 2021 Sep;78(3):333-334. doi: 10.1053/j.ajkd.2021.04.003. Epub 2021 May 28. No abstract available.
- Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, Mercer A, Appel GB, Donadio JV, Floege J, Li PKT, Maes BD, Locatelli F, Praga M, Schena FP, Levey AS, Greene T. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. Am J Kidney Dis. 2021 Sep;78(3):340-349.e1. doi: 10.1053/j.ajkd.2021.03.007. Epub 2021 Mar 26.
- Lambers Heerspink HJ, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1079-88. doi: 10.2215/CJN.11511114. Epub 2015 Apr 17.
- Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28.
- Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.
- Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73. doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24.
- Marup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin Kidney J. 2023 Sep 26;17(1):sfad249. doi: 10.1093/ckj/sfad249. eCollection 2024 Jan.
- Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.
- Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
- 中华医学会糖尿病学分会, 国家基层公共卫生服务项目基础糖尿病防治管理办公室. 国家基层糖 尿病肾脏病防治技术指南 (2023). 中华内科杂志, 2023, 62(12): 1394-1405
- American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010.
- Yang C, Wang H, Zhao X, Matsushita K, Coresh J, Zhang L, Zhao MH. CKD in China: Evolving Spectrum and Public Health Implications. Am J Kidney Dis. 2020 Aug;76(2):258-264. doi: 10.1053/j.ajkd.2019.05.032. Epub 2019 Sep 3.
- Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, Zhang X, Li C, Huang Z, Sun X, Wang L, Zhou M, Wu J, Wang Y. Prevalence and Treatment of Diabetes in China, 2013-2018. JAMA. 2021 Dec 28;326(24):2498-2506. doi: 10.1001/jama.2021.22208.
- IDF ATLAS REPORTS: Diabetes and Kidney Disease- 2023. www.diabetesatlas.org
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças do Sistema Endócrino
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Doenças Metabólicas
- Distúrbios da micção
- Manifestações Urológicas
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Insuficiência renal
- Proteinúria
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Diabetes Mellitus, Tipo 2
- Insuficiência Renal Crônica
- Albuminúria
- FineRenona
Outros números de identificação do estudo
- [2026C]IIT No.001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .